patent expiry for GLP-1 drugs across markets Company Molecule Brand Name Mode of administration First US Patent Expiry Canada Brazil India Novo Semaglutide Ozempic Injectable 2031 Jan 2026 Mar 2026 Mar 2026 Novo Semaglutide Wegovy Injectable 2031 Jan 2026 Mar 2026 Mar 2026 Novo Semaglutide Rybelsus Oral 2031 Jan 2026 Mar 2026 Mar 2026 Eli Lilly Tirzepatide Mounjaro Injectable 2036 2036 2036 2036 Eli Lilly Tirzepatide Zepbound Injectable 2036 2036 2036 2036 Positioning of Indian Pharma companies in GLP-1s company positioning Shaily Engineering Leading manufacturer of pen injectors for GLP-1 therapies
In theory, combining agents that both reduce adiposity and improve insulin sensitivity could produce additive or synergistic metabolic effects but this is entirely speculative and unproven in humans
Guided sessions for cravings, sleep, and the emotional weather of the journey
Earlier-stage evidence base
Both approaches should include regular monitoring of key safety parameters including heart rate, blood pressure, kidney function, and signs of pancreatitis or gallbladder disease
[1] [2] Some patients report feeling more tired when starting Saxenda, particularly if they are also following a reduced-calorie diet